bevacizumab + etoposide + utidelone

This is a combination therapy consisting of three agents: - **Bevacizumab** is a recombinant humanized monoclonal IgG1 antibody that inhibits vascular endothelial growth factor (VEGF), thereby blocking angiogenesis and tumor blood vessel formation. - **Etoposide** is a cytotoxic small molecule chemotherapeutic agent that inhibits topoisomerase II, leading to DNA strand breaks and apoptosis in cancer cells. - **Utidelone** (UTD1) is an epothilone analog, functioning as a microtubule-stabilizing agent similar to taxanes but with the ability to cross the blood-brain barrier due to its physiochemical properties and resistance to P-glycoprotein-mediated efflux. This combination has been investigated primarily for HER2-negative breast cancer patients with brain metastases. Clinical trials have shown promising central nervous system overall response rates and manageable toxicity profiles. Utidelone's unique ability to penetrate the blood-brain barrier makes this regimen particularly relevant for treating brain metastases from breast cancer[1][3][4][5].